Melior Discovery Inc (Exton, PA) has pioneered a unique, optimized, high throughput pharmacology platform that is able to systematically identify novel indications for pre-clinical and development stage drug candidates. Melior also applies this expertise to the provision of a range of essential pre-clinical and discovery services for clients in the pharmaceutical and biopharmaceutical industries, including pharmacokinetic evaluations, efficacy models and bioanalytical testing.
Melior's theraTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently, over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. In most cases, Melior's theraTRACE® system is able to provide a complete pharmacological profile of a compound in 10 weeks. theraTRACE® has found particular utility in facilitating the crucial "go/no go" development decisions routinely faced by pharmaceutical and biopharmaceutical companies. In addition to the theraTRACE® indications discovery platform, Melior is able to extend its high throughput pharmacology approach to customized in vivo efficacy evaluations in other focused therapeutic areas.